VANCOUVER, British Columbia, June 29, 2017 /PRNewswire/ -- According to a new series of reports on the U.S. market for soft tissue reinforcement and regeneration devices market by iData Research (www.idataresearch.com), the proportion of Americans affected by obesity and diabetes is increasing. As a result, the incidences of diabetic foot ulcers will rise dramatically in the country. This will fuel the demand for skin repair devices for the treatment of this common type of diabetic foot pathology, which comprises approximately 80% of all lower extremity amputations. Skin substitutes may be indicated for use on burns or other chronic wounds, including venous leg ulcers and diabetic ulcers.
"Individuals at risk of developing chronic wounds are the elderly, those with chronic venous disease, diabetics and those who develop ulcers on tissue over bony prominences as a result of extended immobility," explains Jeffrey Wong, Strategic Analyst Manager at iData Research. "This increases the number of potential patients from the low thousands to millions."
Soft tissue augmentation and reinforcement devices add significant costs to suture-based repair procedures. The cost varies, depending on the type of device used and the repair being performed, but in general, biological devices, such as allografts and xenografts, cost significantly more than synthetic devices within the same market segment. For instance, biological devices may offer superior long-term benefits in hernia repair by avoiding risks of infection and premature degradation and failure, but their high cost continues to deter surgeons from using them broadly, limiting the sales of the more expensive allografts and xenografts in uncomplicated hernia repair. Until biological devices can provide a better cost-benefit ratio, synthetic meshes will remain dominant in the hernia repair market.
However, with limited medical reimbursement in the U.S., high cost becomes a significant deterrent to overall sales. Because augmentation and reinforcement devices for tendon repair are expensive and clinical evidence is not completely compelling, third parties are reluctant to provide reimbursement. This discourages the use of these products in more cost-conscious settings. As a result, the surgical center must absorb all or part of the cost of the device into the total cost of the surgery itself; this may not be an option for facilities with constrained budgets. These issues are also apparent in the skin repair market, where recent changes in reimbursement will limit growth of this market in the future.
LifeCell is the leading competitor in the U.S. soft tissue reinforcement and regeneration device market and continues to devote efforts to penetrate markets with other existing products while developing and commercializing additional tissue matrix devices and applications to expand into new markets and geographies. In May 2016, LifeCell released the latest, enhanced version of its acellular dermal matrix, AlloDerm® SELECT™. AlloDerm® SELECT™ comes in two varieties: the RTM and the DUO™, with the former offering additional thickness options and the latter offering advanced cutting options for more precise and customized treatment.
C. R. Bard is among the top three overall competitors in the market, thanks to its array of products used in various applications across different soft tissue segments. The company's broad range of hernia repair products allowed it to be one of the top players in this market. Additional competitors in the U.S. market for soft tissue reinforcement and regeneration devices include Acelity, Ethicon, MiMedx, Integra LifeSciences, Covidien, Organogenesis and Boston Scientific among others.
For Further Information
More on the soft tissue reinforcement and regeneration market in U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Soft Tissue Reinforcement and Regeneration Devices. The full report suite includes reports on the following markets: breast reconstruction, hernia repair, dural repair, vaginal slings, skin repair, sports medicine and tendon reinforcement and dental soft tissue regeneration.
The iData report series on soft tissue reinforcement and regeneration devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxembourg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about soft tissue reinforcement and regeneration market data, register online or email us at email@example.com for a U.S. Market Report Suite for Soft Tissue Reinforcement and Regeneration Devices brochure and synopsis.
About iData Research
iData Research (www.idataresearch.com) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Wound Management, Orthopedic Soft Tissue, Orthopedic Biomaterials, Orthopedic Soft Tissue Reinforcement and Regeneration, Spinal Implants and VCF, Spinal MIS, Orthopedic Trauma, Large & Small Joints, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Anesthesiology, Orthopedics and more.
We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.
iData Research Inc.
604-266-6933 Ext. 205
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifecell-cr-bard-leads-us-market-for-soft-tissue-reinforcement-and-regeneration-fueled-by-prevalence-of-obesity-and-diabetes-300482019.html
SOURCE iData Research